Illumina and ReaMetrix formed a diagnostic collaboration under which the companies will co-develop molecular diagnostic panels for a range of disease areas. ReaMetrix will gain non-exclusive rights to market the resulting panels in India. Illumina will retain rights to market the tests outside of India.
Illumina will supply VeraCode™ technology and other reagents for the tests. ReaMetrix will develop, validate, and market diagnostic panels based on Illumina’s upcoming BeadXpress™ platform, scheduled for market introduction before the end of the year.
According to Bala Manian, Ph.D., CEO, ReaMetrix, “India’s rapidly emerging healthcare system presents a tremendous opportunity to leapfrog current diagnostics and chart a new path innovative molecular and pharmacogenomic testing.”
Bill Craumer, Illumina, told GEN that “the Indian digsnostic market has enormous long-term potential and working with ReaMetrix gave us the opportunity to tap into a world class company that can market directly to the Indian population. We expect to make progress on our development objectives for molecular diagnostics, producing additional tests that we could market to the rest of the world. Market success in India would have a potentially broad global benefit.”
